Erratum: Synthetic human parathyroid hormone1-34 replacement therapy: A Randomized crossover trial comparing pump vs injections in the treatment of chronic hypoparathyroidism (Journal of Clinical Endocrinology and Metabolism (2012) 97:2 (391-399) DOI: 10.1210/jc.2011-1908);Synthetic human parathyroid hormone 1-34 replacement therapy: A randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 2, 2012, Pages 391-399

  Winer, Karen K ^a   Zhang, Bo ^a   Shrader, Joseph A ^a   Peterson, Donna ^a   Smith, Michaele ^a   Albert, Paul S ^a   Cutler, Gordon B ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CALCITRIOL; CALCIUM; CYCLIC AMP; MAGNESIUM; MINERAL; PARATHYROID HORMONE[1-34]; PYRIDINIUM DERIVATIVE;

ADULT; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; FATIGUE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOPARATHYROIDISM; INJECTION SITE ERYTHEMA; INSULIN PUMP; MAGNESIUM BLOOD LEVEL; MAGNESIUM URINE LEVEL; MALE; MINERAL BLOOD LEVEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VITAMIN BLOOD LEVEL;

EID: 84863029403     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1908     Document Type: Erratum

References (36)

1. Langdahl BL, Mortensen L, Vesterby A, Eriksen EF, Charles P 1996 Bone Histomorphometry in hypoparathyroid patients treated with vitamin D. Bone 18:103-108 (Pubitemid 26092589)
2. Weber G, Cazzuffi MA, Frisone F, de Angelis M, Pasolini D, Tomaselli V, Chiumello G 1988 Nephrocalcinosis in children and adolescents: sonographic evaluation during long-term treatment with 1,25-dihydrocholecalciferol. Child Nephrol Urol 9:273-276 (Pubitemid 20071422)
3. Santos F, Smith MJ, Chan JC 1986 Hypercalciuria associated with long term administration of calcitriol (1,25-dihydroxyvitamin D). Am J Dis Child 140:139-142 (Pubitemid 16165713)
4. Litvak J Moldwer MP, Forbes AP, Henneman PH 1958 Hypocalcemic hypercalciuria during vitamin D and dihydrotachysterol therapy of hypoparathyroidism. J Clin Endocrinol Metab 18:246-252
5. Horwitz MJ, Stewart AF 2008 Hypoparathyroidism: is it time for replacement therapy? J Clin Endocrinol Metab 93:3307-3309
6. Yamamoto M, Akatsu T, Nagase T, Ogata E 2000 Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain of function mutations in the calcium sensing receptor: Is it possible to differentiate the two disorders? J Clin Endocrinol Metab 85:4583-4591 (Pubitemid 32157637)
7. Winer KK, Yanovski JA, Cutler Jr GB 1996 Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism: Results of a randomized crossover trial. JAMA 276:631-636 (Pubitemid 26278069)
8. Winer KK, Yanovski JA, Sarani B, Cutler Jr GB 1998 A randomized, crossover trial of once-daily vs twice-daily human parathyroid hormone 1-34 in the treatment of hypoparathyroidism. J Clin Endocrinol Metab 83:3480-3486 (Pubitemid 28500875)
9. Kanis JA, Russell RG 1977 Rate of reversal of hypercalcemia and hypercalciuria induced by vitamin D and its 1α-hydroxylated derivatives. Br Med J 1:78-81 (Pubitemid 8017507)
10. Quack I, Zwernemann C, Weiner SM, Sellin L, Henning BF, Waldherr R, Büchner NJ, Stegbauer J, Vonend O, Rump LC 2005 Dihydrotachysterol therapy for hypoparathyroidism: consequence of inadequate monitoring. Five cases and a review. Exp Clin Endocrinol Diabetes 113:376-380 (Pubitemid 41059232)
11. Walker Harris V, Jan De Beur S 2009 Postoperative hypoparathyroidism: medical and surgical therapeutic options. Thyroid 19:967-973
12. Shoback D 2008 Clinical practice. Hypoparathyroidism. N Engl J Med 359:391-403
13. Winer KK, Sinaii N, Peterson D, Sainz Jr B, Cutler Jr GB 2008 Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab 93:3389-3395
14. Winer KK, Ko CW, Reynolds JC, Dowdy K, Keli M, Peterson D, Gerber LH, McGarvey C, Cutler Jr GB 2003 Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 88:4214-4220 (Pubitemid 37153722)
15. Winer KK, Sinaii N, Reynolds, J, Peterson D, Dowdy, K, Cutler Jr GB 2010 Long-term treatment of 12 children with chronic hypoparathyroidism: A randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab 95:2680-2688
16. Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L 2011 The effect of adding PTH (1-84) to conventional treatment of hypoparathyrodism: a randomized, placebo controlled study. J Bone Miner Res 26:2358-2370
17. Rubin MR, Sliney Jr J, McMahon DJ, Silverberg SJ, Bilezikian JP 2010 Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int 21:1927-1934
18. Samuels MH, Veldhuis J, Cawley C, Urban RJ, Luther M, Bauer R, Mundy G 1993 Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis. J Clin Endocrinol Metab 77:399-403 (Pubitemid 23230047)
19. Harms HM, Kaptaina U, Külpmann WR, Brabant G, Hesch RD 1989 Pulse amplitude and frequency modulation of parathyroid hormone in plasma. J Clin Endocrinol Metab 69:843-851 (Pubitemid 19245866)
20. Linglart A, Rothenbuhler A, Gueorgieva I, Lucchini P, Silve C, Bougnères P 24 August 2011 Long-term results of continuous subcutaneous recombinanat PTH 1-34 infusion in children with refractory hypoparathyroidism. J Clin Endocrinol Metab jc.2011-1359
21. Brodehl J, Krause A, Hoyer PF 1988 Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol 2:183-189
22. Peacock M, Nordin BE 1968 Tubular reabsorption of calcium in normal and hypercalciuric subjects. J Clin Pathol 21:353-358
23. Drouin JM, Valovich-mcLeod TC, Shultz SJ, Gansneder BM, Perrin DH 2004 Reliability and validity of the Biodex system 3 pro isokinetic dynamometer velocity, torque and position measurements. Eur J Appl Physiol 91:22-29 (Pubitemid 38292346)
24. Muscular Weakness Assessment 1996 Use of normal isometric strength data. The National Isometric Muscle Strength (NIMS) Database Consortium. Arch Phys Med Rehabil 77:1251-1255
25. American Thoracic Society 2002 ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111-117
26. Hann DM, Jacobsen PB, Azzarello LM, Martin SC, Curran SL, Fields KK, Greenberg H, Lyman G 1998 Measurement of fatigue in cancer patients: Development and validation of the fatigue symptom inventory. Quality of Life Research 7:301-310 (Pubitemid 28207019)
27. Hann DM, Denniston MM, Baker F 2000 Measurement of fatigue in cancer patients: further validation of the fatigue symptom inventory. Qual Life Res 9:847-854 (Pubitemid 32209799)
28. Stroebel AM, Bergner M, Reulbach U, Biermann T, Groemer TW, Klein I, Kornhuber J 2010 Statistical methods for detecting and comparing periodic data and their application to the nycthemeral rhythm of bodily harm: a population-based study. J Circ Rhythms 8:10
29. Albert PS, Hunsberger S 2005 On analyzing circadian rhythms data using nonlinear mixed models with harmonic terms. Biometrics 61:1115-1122
30. Pinheiro JC, Bates DM 2000 Mixed-effects models in S and S-Plus. New York: Springer Verlag
31. Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, Allolio B 2002 Well-being, mood, and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 146:215-222 (Pubitemid 34162914)
32. Sikjaer T, Rejnmark L, Mosekilde L 2011 PTH treatment in hypoparathyroidism. Curr Drug Saf 6:89-99
33. Puig-Domingo M, Díaz G, Nicolau J, Fernández C, Rueda S, Halperin I 2008 Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide. Eur J Endocrinol 159:653-657
34. Tashjian Jr AH, Goltzman D 2008 Perspective on the interpretation of rat carcinogenicity studies for human PTH 1-34 and human PTH 1-84. J Bone Miner Res 23:803-811 (Pubitemid 351768798)
35. Tashjian Jr AH, Gagel RF 2006 Teriperitide: 2.5 years of experience on the use and safety of the drug from treatment of osteoporosis. J Bone Miner Res 21:354-365
36. Tashjian Jr AH, Chabner BA 2002 Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 17:1151-1161 (Pubitemid 34680490)